Market Insights
Cirrhosis is a chronic disorder in which the liver slowly gets scarred and damaged over time. These deficient scar tissues then replace existing good liver tissues, affecting the normal functioning of the liver. Cirrhosis leads to liver failure as it progresses with time because it is a slow-moving condition that usually takes several years to develop. If left unchecked, scar tissue will eventually prevent the liver from functioning. Even while the liver cells survive or create new cells capable of producing and removing chemicals from the blood, they do not have a stable connection with the blood.
As per the findings of the National Institutes of Health, the United States finds cirrhosis disease in 1 in every 400 people. In addition, men are more likely than women to be affected. Life expectancy in advanced cirrhosis patients usually spans from 6 months to 2 years, depending on factors such as the complication level of the patient and the availability of donors.
Report Key Takeaways
Recommended Treatment for Cirrhosis:
Eradication of the etiological factor
The core therapeutic strategy for all patients with aCLD is eradicating the etiological factors that cause the liver injury. It is among the only successful antifibrotic approach for the target disease. Successful etiological treatment has been demonstrated in individuals with compensated cirrhosis to reduce portal hypertension, avoid decompensating, and improve outcomes. However, even after an etiological cure, patients with decompensated cirrhosis are less uniform.
Liver transplantation
Cirrhosis might lead your liver to stop working entirely. Liver failure is the medical term for this condition. A liver transplant treatment involves your sick liver being replaced with a healthy liver from a donor. You can wait for a deceased donor or receive a piece of liver from a living relative or acquaintance. However, the waiting list for a transplant is expanding due to a shortage of deceased-donor organs to satisfy rising demand.
Recent Developments Related to Cirrhosis
- Galecto Biotech, Inc. has successfully completed their Phase 1b/2a GULLIVER-2 trial in which Part 1 was targeted by the company. The trials have evaluated patients’ pharmacokinetics, safety, and tolerability of the oral galectin-3 inhibitor GB1211. The company has also initiated Part 2 of this trial for the research program, a double-blind and 12-week randomized trial intended to observe the effectiveness of GB1211. The Phase 1b/2a GULLIVER-2 trial, liver cirrhosis, is the first in the Galectos for GB1211.
- As per the latest recent study conducted by some researchers from The Medical University of Vienna, functional magnetic resonance imaging can act as an effective resource for finding the complications in chronic liver disease. A multidisciplinary team of researchers from the Department of Medicine III and Department of Biomedical Imaging has conducted a study on different patients from the liver cirrhosis outpatient clinic of the University.
Major Players Working on Cirrhosis
AstraZeneca, Encoded Therapeutics, Beam Therapeutics, Anima Biotech, Dicerna Pharmaceuticals, Cyclerion, Reveal Pharmaceuticals, Unity Biotechnology, and Alnylam Pharmaceuticals are some of the liver disease therapeutics companies.
Key Reasons to Purchase This Report
- The pipeline insight’s primary objective is to provide authentic information regarding therapies and drugs that are effective for cirrhosis patients and assess its recent results.
- An in-depth discussion on the latest clinical practices and therapeutic trials taking place in different regions of the world, featuring the most validated data by industry experts.
- An overview of advanced cirrhosis drugs that are under development in different stages, and shedding light on the respective companies developing the respective drugs.
